Axsome Therapeut Stock Price, News & Analysis

Axsome Therapeutics (NASDAQ: AXSM) announced that CEO Herriot Tabuteau will participate in a virtual fireside chat at the Cowen 42^nd Annual Health Care Conference on March 7, 2022, at 10:30 AM Eastern Time. A live webcast and archive will be available on the Company’s website. Axsome focuses on developing innovative therapies for central nervous system disorders, aiming to improve treatment options for patients. The Company is committed to transforming CNS treatment through its novel mechanisms of action.

Axsome Therapeutics (NASDAQ: AXSM) announced its fourth-quarter and full-year financial results for 2021, highlighting a net loss of $34 million, or $(0.90) per share, compared to a loss of $29.2 million, or $(0.78) per share, in Q4 2020. R&D expenses decreased to $13.8 million, attributed to the conclusion of clinical trials. The company is advancing its pipeline, with NDAs for AXS-05 for major depressive disorder and AXS-07 for migraines under FDA review, with a PDUFA date of April 30, 2022. Axsome ended 2021 with $86.5 million in cash, having accessed $20 million from its ATM equity facility in February 2022.

Axsome Therapeutics (NASDAQ: AXSM) will report its Q4 and fiscal year 2021 financial results on March 1, 2022, before U.S. market opening. A conference call is scheduled for 8:00 AM ET on the same day to discuss these results and provide a business update. The event can be accessed via a live webcast on the company’s website. Axsome is focused on developing novel therapies for central nervous system disorders. The press release includes forward-looking statements regarding clinical trial outcomes and regulatory approvals, highlighting potential risks and uncertainties.

Axsome Therapeutics (NASDAQ: AXSM) announced that CEO Herriot Tabuteau will engage in a virtual fireside chat during the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. The event will focus on the company’s innovative therapies for central nervous system disorders. A live webcast and archive will be available on the company’s website. Axsome is dedicated to developing unique treatment options to enhance patient care, targeting conditions with limited therapies.

Axsome Therapeutics reported its third quarter 2021 financial results, highlighting the advancement of its CNS products. The FDA is currently reviewing the NDA for AXS-05 in depression, while the NDA for AXS-07 in migraine has been accepted. The company is preparing for potential launches if approved. Axsome's R&D expenses decreased to $13.2 million, while G&A expenses spiked to $20.2 million, reflecting pre-commercial activities. The net loss rose to $34.9 million. Cash reserves stand at $114.6 million, sufficient to fund operations through 2024.

Axsome Therapeutics (NASDAQ: AXSM) will report its Q3 2021 financial results on November 8, 2021, prior to market opening. A conference call will follow at 8:00 AM ET the same day, aimed at discussing these results along with a business update. Interested participants can join by dialing (844) 698-4029 (domestic) or (647) 253-8660 (international), using conference ID 6365926. The event will also be available via a live webcast on the Company's website, with a recording accessible for 30 days post-event.

Axsome Therapeutics announces an amendment to its term loan facility with Hercules Capital, increasing the loan size to $300 million. Upon potential FDA approval of AXS-05 for major depressive disorder, $100 million will be available immediately. The agreement extends the loan's maturity to October 2026 and interest-only payments up to 60 months. This capital will support the anticipated launches of both AXS-05 and AXS-07, enhancing financial flexibility for the company’s critical therapies.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) has enrolled the first patient in the SYMPHONY trial, a Phase 3 study assessing AXS-12 for narcolepsy. This randomized, double-blind trial aims to evaluate AXS-12's efficacy and safety in about 90 patients, focusing on cataplexy attack frequency. Topline results are expected in early 2023. AXS-12, a selective norepinephrine reuptake inhibitor, has received Orphan Drug Designation from the FDA. The advancement into Phase 3 underscores Axsome's dedication to developing therapies for serious CNS disorders affecting patients' quality of life.

Axsome Therapeutics (NASDAQ: AXSM) announced that the FDA has accepted its New Drug Application (NDA) for AXS-07 to treat acute migraine, with a target decision date of April 30, 2022. AXS-07 is an investigational drug combining MoSEIC meloxicam and rizatriptan, proven in Phase 3 trials to significantly alleviate migraine pain. Over 37 million Americans suffer from migraines, leading to substantial healthcare costs. The company's CEO emphasized the NDA acceptance as a pivotal step toward providing a new treatment option for those affected by this debilitating condition.